- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Management of intraoperative ischemic right ventricular failure not amenable to surgical revascularization during repair of type A aortic dissection (Poster Board Number 14; Exhibit Hall, Street Level) - Jul 12, 2025 - Abstract #ASA2025ASA_2712;
His intraoperative course was complicated by failure of his existing right coronary artery (RCA) saphenous vein graft with no new RCA target available for bypass, resulting in ischemic right ventricular failure. This case report will discuss the subsequent maximal medical management of ischemic right ventricular failure, including veno-arterial extracorporeal membrane oxygenation, intra-aortic balloon pump insertion, vasopressor and inotrope infusions, inhaled epoprostenol, endotracheal milrinone, and additional methods which were not utilized including mechanical RV support devices.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Journal: Chlorine gas induced acute respiratory distress syndrome due to pool shock. (Pubmed Central) - Jun 26, 2025
Targeted therapy for chlorine gas induced lung injury is limited. Despite a rapid decline over his initial clinical course, and prognostic markers all portending a poor outcome, aggressive management of his lung injury with standard ARDS care proved to be effective, and the patient made an excellent recovery.
- |||||||||| AeroFact (AP-002) / Aerogen Pharma
Trial completion date, Trial initiation date, Trial primary completion date: APC-AF-CLN-003: Safety and Efficacy of AeroFact in Preterm Infants With Respiratory Distress Syndrome (clinicaltrials.gov) - Jun 18, 2025
P3, N=260, Not yet recruiting,
Despite a rapid decline over his initial clinical course, and prognostic markers all portending a poor outcome, aggressive management of his lung injury with standard ARDS care proved to be effective, and the patient made an excellent recovery. Trial completion date: Aug 2027 --> May 2029 | Initiation date: Apr 2025 --> Aug 2025 | Trial primary completion date: Aug 2026 --> May 2027
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Review, Journal: Inhaled Epoprostenol for Management of Acute Respiratory Failure and Pulmonary Vascular Disease. (Pubmed Central) - Jun 14, 2025
However, it may be beneficial in certain select patient populations. In the management of pulmonary hypertension, inhaled epoprostenol has allowed for continued maintenance of chronic pulmonary arterial hypertension-specific therapy and for possibly improving right ventricular function as an attractive option in the critical care management of pulmonary hypertension.
- |||||||||| epoprostenol intravenous / Generic mfg.
Maternal Pulmonary Arterial Hypertension Treated With IV Epoprostenol - A Case Report (Area L, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1459) - Feb 24, 2025 - Abstract #ATS2025ATS_5960;
Her pre-gestation medications included Ambrisentan, Selexipag, and Sildenafil...The patient was then transitioned from IV Epoprostenol to inhaled Treprostinil via dry powder inhaler...IV Epoprostenol may be used adjunctively in the management of pregnant PAH patients and could improve peri and postpartum outcomes. This case adds to a growing literature base on this subject; the difficulties of performing a blinded, randomized clinical trial in this cohort are acknowledged.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Rapid Respiratory Compromise Secondary to Atypical Bacterial Pneumonia Leading to Multiorgan Failure and Profound Refractory Shock (Area K, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1326) - Feb 24, 2025 - Abstract #ATS2025ATS_4589;
Subsequently, patient developed profound shock and hypoxia requiring inhaled epoprostenol, paralysis, and proning...Antibiotics were deescalated to penicillin G, clindamycin, and oseltamivir with the addition of IVIG, steroids, and multiple pressors including methylene blue due to concerns for necrotizing pneumonia and toxic shock syndrome...Additionally, the significant mortality rate associated with invasive disease warrants further discussion into additional treatment modalities and early recognition of this pathogen to aid in the cessation of disease progression to multiorgan failure due to toxic shock syndrome. This case aims to highlight a case of a young individual with no comorbid conditions who rapidly progressed despite maximal therapies and focuses on the importance of early recognition in an atypical patient population.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
A Rare Case of Antisynthetase Syndrome and Rapidly Progressive Interstitial Lung Disease (Area K, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1208) - Feb 24, 2025 - Abstract #ATS2025ATS_4177;
Treatments included high-dose methylprednisolone, cyclophosphamide, plasmapheresis, IVIG, tofacitinib, tacrolimus, and mycophenolate mofetil...RP-ILD, which may lead to significant morbidity or fatal outcomes, presents notable treatment challenges with limited options and high associated mortality rates. This case underscores the importance of suspecting ASyS in isolated ILD diagnoses especially in high-risk populations.
- |||||||||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp, VentaProst (epoprostenol inhalation) / Aerogen Pharma
TUMORAL PULMONARY HYPERTENSION SECONDARY TO GI MALIGNANCY - Rachel Wester (Board no. 262; South Hall) - Jan 27, 2025 - Abstract #ACC2025ACC_4931;
Histopathological diagnosis with tissue sampling is the gold standard. The optimal management of PTTM is unclear but prior case reports discuss supportive care, chemotherapy, steroids, oxygen and PAH medications.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Pre LVAD Implantation Assessment Using Right Ventricular - Arterial Coupling Predicts Immediate Right Heart Failure and Need for RVAD (Veterans Memorial Auditorium) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_868;
Early post-operative RHF was defined as a cumulative outcome including the need for RVAD, inhaled epoprostenol > 48 hours, or inotropic support >14 days.Results 146 patients underwent LVAD implant at our institution between 2019 and 2024 (Figure 1)...TTE derived RV-PA coupling was decreased in patients requiring RVAD (median: 0.26 vs 0.17, P=0.003) and who developed RHF (median: 0.33 vs 0.24, P=0.016). Peri-operative TEE RV FW strain < -9.5% was predictive of all-cause mortality (P=0.034) post LVAD implant, but TTE derived metrics did not show significant predictive value.Conclusion Pre-LVAD implantation decreased RV FW strain, and RV-PA coupling can aid with the risk stratification of patients in need of RVAD or immediate RHF.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Thymoglobulin Use as Induction for Positive Crossmatch in the Absence of HLA DSA: Impact of Non-HLA DSA in Lung Transplant (Poster Hall) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_640;
Both received intra-op basiliximab induction immunosuppression (IS) followed by per protocol maintenance IS...Induction IS was changed to rabbit anti-thymocyte globulin (rATG) on post-operative day (POD) 1 and 3 for P1 and P2, respectively...P1 required high dose pressors and inhaled epoprostenol post-transplant, and P2 required early re-intubation for ventilatory support...Induction with rATG may help mitigate non-HLA Ab-induced allograft injury. Further studies are needed to elucidate ideal management of positive XM due to non-HLA Ab.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, VentaProst (epoprostenol inhalation) / Aerogen Pharma
Review, Journal: The Influence of Pulmonary Arterial Hypertension In Pregnancy: A Review. (Pubmed Central) - Sep 10, 2024
Managing PAH in pregnancy requires careful planning, continuous monitoring, and tailored therapeutic strategies to navigate the complex interplay of physiological changes and mitigate risks. Future research should focus on elucidating the pathophysiology of PAH during pregnancy and developing safer, more effective treatments to improve maternal and fetal outcomes.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Trial completion, Trial completion date, Trial primary completion date: Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide (clinicaltrials.gov) - Aug 6, 2024
P4, N=115, Completed,
Future research should focus on elucidating the pathophysiology of PAH during pregnancy and developing safer, more effective treatments to improve maternal and fetal outcomes. Recruiting --> Completed | Trial completion date: Dec 2024 --> Aug 2024 | Trial primary completion date: Dec 2024 --> Aug 2024
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Cesarean Section in Decompensated Heart Failure (Exhibit Hall) - Aug 6, 2024 - Abstract #ASA2024ASA_5716;
Continuous transthoracic echocardiogram was utilized during induction. Postoperatively, she was transferred to the ICU on milrinone, epinephrine, amiodarone, vasopressin, and inhaled epoprostenol.
- |||||||||| AeroFact (AP-002) / Aerogen Pharma
Trial completion: A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (clinicaltrials.gov) - Aug 5, 2024
P2, N=261, Completed,
Postoperatively, she was transferred to the ICU on milrinone, epinephrine, amiodarone, vasopressin, and inhaled epoprostenol. Active, not recruiting --> Completed
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
PERICARDIAL EFFUSION IN PULMONARY ARTERIAL HYPERTENSION: A PERPLEXING PRESENTATION (Convention Center Exhibit Hall: Poster Area 5) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1747;
There is an increased mortality risk of pericardial effusion in PH compared to non-PH patients. With an elevated risk of hemodynamic compromise and death, careful observation of pericardial effusion is of utmost importance.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
THIS COP HAS SCLERODERMA (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1634;
We propose that in cases of ambiguous respiratory failure in young patients that autoimmune serology be performed. In cases of interstitial lung pathologies with evidence of autoimmune serology, moderate dosing of steroids may be beneficial for both treatment and potential narrowing of the diagnosis.
- |||||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J, VentaProst (epoprostenol inhalation) / Aerogen Pharma
Spinal Cord Infarction Associated With VA-ECMO Support (San Diego Convention Center, Room 1A-B (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_7690;
Despite antibiotics and transitioning to IV epoprostenol and inhaled nitric oxide, she progressed to RV failure and shock...PAH patients on peripheral VA-ECMO support often have minimal hypoxia and preserved LV systolic function shifting the mixing interface to the distal aorta. Potential interventions such as cannulation reconfiguration or adjusting ECMO flow to move the mixing interface have been proposed.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Rescue Awake Venovenous Extracorporeal Membrane Oxygenation With Right Ventricular Support in Secondary to COVID-19, A Case Series (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5896;
Despite treatment with inhaled epoprostenol and diuretics, she had worsening hypoxemic respiratory failure that required high flow nasal cannula of 100% FiO2 with declining oxygen saturations...These cases reflect a subset of patients with a high mortality and morbidity, especially if mechanical ventilation is involved in the treatment course. In these selected cases, we believe that early application of VV ECMO improved outcomes by avoiding the complications of mechanical ventilation, rather than using it for salvage therapy in mechanically ventilated patients with refractory hypoxemia.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma, Vecuron (vecuronium) / Sun Pharma
Denied Extracorporeal Membrane Oxygenation Due to Morbid Obesity: A Case Report (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5892;
Emerging evidence suggests elevated BMI may be associated with decreased mortality in ARDS patients on ECMO. More research is needed to prevent inappropriate exclusion of this population.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Systemic Lupus Erythematous Presenting Primarily as Pulmonary Arterial Hypertension (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1553;
Based on her labs and clinical findings she was confirmed to have SLE (thrombocytopenia, pleural and pericardial effusion, low C3, and anti-Smith ab) and started on Plaquenil and steroids...It is important to note that patients with SLE-associated PAH, have a poorer prognosis than those without it. With earlier recognition and the use of vasodilator therapies, the prognosis has improved.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Review, Journal, Surgery: Inhaled Pulmonary Vasodilators for the Treatment of Right Ventricular Failure in Cardio-Thoracic Surgery: Is One Better than the Others? (Pubmed Central) - Jan 23, 2024
The largest ongoing randomized controlled trial on adults (INSPIRE-FLO) is addressing whether inhaled Epoprostenol and inhaled nitric oxide are similar in preventing RVF after heart transplants and left ventricular assist device placement, and whether they are similar in preventing primary graft dysfunction after lung transplants...If severe refractory postoperative RVF occurs, IPVs should be combined with complementary pharmacology (inotropes and inodilators). If unsuccessful, right ventricular mechanical support should be established.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Journal, Surgery: Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery. (Pubmed Central) - Nov 3, 2023
P4
If unsuccessful, right ventricular mechanical support should be established. Among patients undergoing major cardiac surgery for advanced heart failure, inhaled pulmonary-selective vasodilator treatment using iEPO was associated with similar risks for RVF development and development of other postoperative secondary outcomes compared with treatment using iNO.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
An Uncommon Mass, in an Uncommon Location, in a Common Patient? (Zone 4, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_7052;
With approximately fifty cases reported in the literature, most achieved temporary remission. Our approach to management included chemotherapy with decitabine and cytarabine and subsequent external-beam radiotherapy.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Persistent Supra-Systemic Pulmonary Artery Hypertension Following Mitral Valve Replacement (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_5913;
His postoperative course was c/b persistent pulmonary artery hypertension despite use of three pulmonary vasodilators (inhaled epoprostenol, inhaled nitric oxide, and IV treprostinil). On POD7, the patient suffered a PEA arrest following persistent supra-systemic pulmonary artery pressures c/b suspected pulmonary vasculature rupture and inability to achieve ROSC.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Tee Guided Cannulation For Ecpr, In The Ed, With Post-cannulation Impella Placement (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_3758;
He had 2 witnessed cardiac arrest in the ED and was intubated, started on inhaled epoprostenol and cannulated for eCPR via femoral-femoral VA-ECMO in the ED with TEE guidance by anesthesiology shock team...On hospital day 6, ECMO was decannulated. Impella was removed the following day and he was extubated on hospital day 8.
- |||||||||| VentaProst (epoprostenol inhalation) / Aerogen Pharma
Review, Journal: A Narrative Review on the Administration of Inhaled Prostaglandins in Critically Ill Adult Patients With Acute Respiratory Distress Syndrome. (Pubmed Central) - Aug 17, 2023
A literature search of MEDLINE was performed using the following search terms: inhaled prostaglandins, inhaled epoprostenol, inhaled nitric oxide, ARDS, critically ill...The use of inhaled prostaglandins can be considered in critically ill patients with COVID-19-associated ARDS or non-COVID-19 ARDS who are experiencing difficulties with oxygenation refractory to nonpharmacologic strategies. The use of iEPO and other inhaled prostaglandins requires further investigation to fully elucidate their effects on clinical outcomes, but it appears these medications may have a potential benefit in COVID-19-associated ARDS and non-COVID-19 ARDS patients with refractory hypoxemia but with little effect on mortality.
|
